Last reviewed · How we verify
IMR-687
Potassium channel opener
Potassium channel opener Used for Treatment of sickle cell disease.
At a glance
| Generic name | IMR-687 |
|---|---|
| Sponsor | Cardurion Pharmaceuticals, Inc. |
| Drug class | Potassium channel opener |
| Target | KCNQ1 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
IMR-687 is a small molecule that acts as a potent opener of the KCNQ1 potassium channel, which is involved in the regulation of cardiac repolarization.
Approved indications
- Treatment of sickle cell disease
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- A Study of IMR-687 in Healthy Adult Volunteers (PHASE1)
- A Study of IMR-687 in Subjects With Beta Thalassemia (PHASE2)
- A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) (PHASE2)
- A Study of IMR-687 in Subjects With Sickle Cell Disease (PHASE2)
- Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction (PHASE2)
- An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |